Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
07 February 2019Website:
http://www.alector.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 20:09:56 GMTDividend
Analysts recommendations
Institutional Ownership
ALEC Latest News
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Alector (ALEC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Some of the worst and most deadly diseases affect our brains. In multiple sclerosis, the immune system “causes communication problems between your brain and the rest of your body,” preventing some victims from walking.
Alector, Inc. expects results from its phase 2 INVOKE-2 study, using AL002 for the treatment of patients with Alzheimer's disease, in Q4 of 2024. IND clearance received to begin a phase 2 study using AL101 for the treatment of patients with Alzheimer's Disease. The global market for Alzheimer's Disease is expected to reach $15.5 billion by 2031.
The heavy selling pressure might have exhausted for Alector (ALEC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.
The average of price targets set by Wall Street analysts indicates a potential upside of 102% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Alector (ALEC) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.81 per share. This compares to earnings of $0.12 per share a year ago.
What type of business is Alector?
Alector, Inc. is a clinical-stage biopharmaceutical company that is developing ways to treat neurodegenerative diseases using expertise in neurology, immunology, and human genetics. Founded in 2013 with headquarters in South San Francisco. The company calls itself a pioneer in immuno-neurology - a new therapeutic approach to treating neurodegeneration that considers immune dysfunction as the root cause of many pathologies that drive degenerative brain diseases. The company is developing treatments that simultaneously counteract these pathologies and restore the brain's immune system. Alector has developed its own Discovery platform, which uses large sets of human genetic data, advanced tools in bioinformatics and visualization, and developments in neurodegeneration and immunology.
What sector is Alector in?
Alector is in the Healthcare sector
What industry is Alector in?
Alector is in the Biotechnology industry
What country is Alector from?
Alector is headquartered in United States
When did Alector go public?
Alector initial public offering (IPO) was on 07 February 2019
What is Alector website?
https://www.alector.com
Is Alector in the S&P 500?
No, Alector is not included in the S&P 500 index
Is Alector in the NASDAQ 100?
No, Alector is not included in the NASDAQ 100 index
Is Alector in the Dow Jones?
No, Alector is not included in the Dow Jones index
When does Alector report earnings?
The next expected earnings date for Alector is 02 August 2024